针对癌症中的动态 HSP90 复合物。
Targeting the dynamic HSP90 complex in cancer.
机构信息
Medical Oncology Branch Center for Cancer Research, National Cancer Institute, Building 10, room 1-5940, 9000 Rockville Pike, Bethesda, MD 20892, USA.
出版信息
Nat Rev Cancer. 2010 Aug;10(8):537-49. doi: 10.1038/nrc2887.
Abstract
The molecular chaperone heat shock protein 90 (HSP90) has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90. However, although recent reports of the early clinical efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiology.
摘要
分子伴侣热休克蛋白 90（HSP90）已被癌细胞用于促进众多癌蛋白的功能，因此可以说癌细胞对 HSP90“上瘾”。然而，尽管最近 HSP90 抑制剂早期临床疗效的报告令人鼓舞，但 HSP90 靶向治疗的最佳应用将取决于对 HSP90 调节的复杂性以及 HSP90 参与肿瘤和正常细胞生理的程度的理解。
相似文献
1
Targeting the dynamic HSP90 complex in cancer.
Nat Rev Cancer. 2010 Aug;10(8):537-49. doi: 10.1038/nrc2887.
2
Structure, function and regulation of the hsp90 machinery.
Biomed J. 2013 May-Jun;36(3):106-17. doi: 10.4103/2319-4170.113230.
3
Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Adv Cancer Res. 2016;129:31-50. doi: 10.1016/bs.acr.2015.09.002. Epub 2015 Oct 23.
4
Targeting Hsp90 in urothelial carcinoma.
Oncotarget. 2015 Apr 20;6(11):8454-73. doi: 10.18632/oncotarget.3502.
5
Targeting HSP90 for cancer therapy.
Br J Cancer. 2009 May 19;100(10):1523-9. doi: 10.1038/sj.bjc.6605066. Epub 2009 Apr 28.
6
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.
Drug Resist Updat. 2009 Feb-Apr;12(1-2):17-27. doi: 10.1016/j.drup.2008.12.002.
7
Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
Oncotarget. 2013 Jul;4(7):1065-74. doi: 10.18632/oncotarget.1099.
8
Hsp90 molecular chaperone inhibitors: are we there yet?
Clin Cancer Res. 2012 Jan 1;18(1):64-76. doi: 10.1158/1078-0432.CCR-11-1000.
9
HSP90 inhibitors for cancer therapy and overcoming drug resistance.
Adv Pharmacol. 2012;65:471-517. doi: 10.1016/B978-0-12-397927-8.00015-4.
10
Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Curr Drug Targets. 2017;18(13):1572-1585. doi: 10.2174/1389450117666160527125522.
引用本文的文献
1
Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives.
Pharmaceuticals (Basel). 2025 Jul 22;18(8):1083. doi: 10.3390/ph18081083.
2
A Novel Small-Molecule GRP94 Modulator Increases PCSK9 Secretion and Promotes LDLR Degradation.
Life (Basel). 2025 Aug 20;15(8):1321. doi: 10.3390/life15081321.
3
S-Nitrosylation in Cardiovascular Disorders: The State of the Art.
Biomolecules. 2025 Jul 24;15(8):1073. doi: 10.3390/biom15081073.
4
Targeting macrophage migration inhibitory factor as a potential therapeutic strategy in colorectal cancer.
Oncogenesis. 2025 Aug 20;14(1):30. doi: 10.1038/s41389-025-00572-3.
5
Integrating deep learning for post-translational modifications crosstalk on Hsp90 and drug binding.
J Biol Chem. 2025 Jul 25;301(9):110519. doi: 10.1016/j.jbc.2025.110519.
6
Extracellular vesicles: the "Trojan Horse" within breast cancer host microenvironments.
Mol Cancer. 2025 Jun 23;24(1):183. doi: 10.1186/s12943-025-02358-y.
7
Hsp90 C-terminal domain inhibition enhances ferroptosis by disrupting GPX4-VDAC1 interaction to increase HMOX1 release from oligomerized VDAC1 channels.
Redox Biol. 2025 May 29;85:103672. doi: 10.1016/j.redox.2025.103672.
8
Role of HSF1 in cell division, tumorigenesis and therapy: a literature review.
Cell Div. 2025 Apr 26;20(1):11. doi: 10.1186/s13008-025-00153-1.
9
Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma.
NPJ Precis Oncol. 2025 Apr 25;9(1):122. doi: 10.1038/s41698-025-00915-8.
10
The function of chaperones in the radioresistance of glioblastoma: a new insight into the current knowledge.
Brain Tumor Pathol. 2025 Apr 21. doi: 10.1007/s10014-025-00501-7.
本文引用的文献
1
Post-translational modification of heat-shock protein 90: impact on chaperone function.
Expert Opin Drug Discov. 2007 Oct;2(10):1403-14. doi: 10.1517/17460441.2.10.1403.
2
Hsp90 phosphorylation, Wee1 and the cell cycle.
Cell Cycle. 2010 Jun 15;9(12):2310-6. doi: 10.4161/cc.9.12.12054.
3
Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone?
Cell Cycle. 2010 Apr 15;9(8):1542-50. doi: 10.4161/cc.9.8.11204.
4
Heat shock protein 70 (hsp70) as an emerging drug target.
J Med Chem. 2010 Jun 24;53(12):4585-602. doi: 10.1021/jm100054f.
5
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
J Clin Oncol. 2010 Mar 20;28(9):1520-6. doi: 10.1200/JCO.2009.25.0415. Epub 2010 Feb 22.
6
Asymmetric activation of the hsp90 dimer by its cochaperone aha1.
Mol Cell. 2010 Feb 12;37(3):344-54. doi: 10.1016/j.molcel.2010.01.006.
7
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.
Mol Cell. 2010 Feb 12;37(3):333-43. doi: 10.1016/j.molcel.2010.01.005.
8
The molecular chaperone Hsp90 regulates accumulation of DNA polymerase eta at replication stalling sites in UV-irradiated cells.
Mol Cell. 2010 Jan 15;37(1):79-89. doi: 10.1016/j.molcel.2009.12.015. Epub 2010 Jan 14.
9
Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
PLoS One. 2010 Jan 25;5(1):e8859. doi: 10.1371/journal.pone.0008859.
10
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
Leukemia. 2010 Apr;24(4):699-705. doi: 10.1038/leu.2009.292. Epub 2010 Jan 28.
Zotero 插件